GENOMIC VARIABILITY IN PATIENTS WITH DUCTAL FORM OF BREAST CANCER AND THE POSSIBILITY OF CORRECTION THE PEPTIDE BIOREGULATOR AND METAL IONS

• Published in: Georgian medical news no. 262; p. 88
• Main Authors: Jokhadze, T, Monaselidze, J, Nemsadze, G, Buadze, T, Gaiozishvili, M, Lezhava, T
• Format: Journal Article
• Language: Russian
• Published: Georgia (Republic) 01-01-2017
• Subjects: Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - pathology; Carcinoma, Ductal, Breast - drug therapy; Carcinoma, Ductal, Breast - genetics; Carcinoma, Ductal, Breast - pathology; Cations, Divalent; Chromatin - drug effects; Chromatin - ultrastructure; Chromosome Aberrations - drug effects; Chromosome Fragile Sites; Drug Synergism; Female; Genetic Variation; Humans; Nickel - pharmacology; Oligopeptides - pharmacology; Tumor Cells, Cultured - drug effects
• ISSN: 1512-0112

Level of genome stability (structural aberrations, aneuploidy and fragile sites) was studied in cells of the lymphocyte culture of ductal breast cancer patients (DBC). Was studied the correctional influence of separate and combinative action of peptide bioregulator (Ala-Glu-Asp-Gly) and heavy metal - nickel. It is shown that DBC patients are characterized by high level of genome instability, which is the result of the chromatin changing state. The used tests makes it possible to conclude that in the case of this form of cancer subordinates to specific epigenetic variation as a hetero- also euchromatic regions of genome. The agents - peptide bioregulator (Ala-Glu-Asp-Gly) and nickel ions, used in cell culture of ductal breast cancer patients, revealed the protective effect what indicates the prospects to further study for their involving purpose in combined therapy of this form of cancer.